Silicon-based agent mitigates fatty liver formation in a CDAHFD60-induced MASH mouse model by enhancing hepatic function.
Yoshihisa Koyama, Yuki Kobayashi, Ikuei Hirota, Hikaru Kobayashi, Shoichi Shimada · Biochemistry and biophysics reports · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In mice, the Si–based agent generates molecular hydrogen in the intestine and has previously been shown to alleviate symptoms in various oxidative stress–related disease models, including ulcerative colitis, Parkinson's disease, intestinal ischemia–reperfusion injury, and interstitial pneumonia. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how hydrogen-supplemented jelly intake affected the outcomes measured in mice. The Si–based agent generates molecular hydrogen in the intestine and has previously been shown to alleviate symptoms in various oxidative stress–related disease models, including ulcerative colitis, Parkinson's disease, intestinal ischemia–reperfusion injury, and interstitial pneumonia.
What the Researchers Studied
The researchers studied mice. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 12 weeks. The Si–based agent generates molecular hydrogen in the intestine and has previously been shown to alleviate symptoms in various oxidative stress–related disease models, including ulcerative colitis, Parkinson's disease, intestinal ischemia–reperfusion injury, and interstitial pneumonia.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The study used a preclinical animal experiment. The hydrogen delivery method was hydrogen-supplemented jelly intake. The reported treatment duration was 12 weeks.
Limitations and Safety
Reported limitations: However, because the Si-based agent was administered as part of the diet, the possibility that it influenced MASH induction cannot be excluded, representing a limitation of this study. 5 A limitation of this study is the use of the CDAHFD60-induced MASH mouse model, which does not fully reproduce the metabolic features of human MASH, such as obesity and insulin resistance [ 12 ]. Second limitation of this study is that oxidative stress was assessed only systemically using serum-based d-ROMs and BAP assays, and not directly in liver tissue. Safety information: Given that neither the Si-based agent nor the molecular hydrogen it generates has been associated with adverse effects, this agent holds promise as a novel and safe therapeutic candidate for MASH.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.